Literature DB >> 9163705

Infrequent mutations of the transforming growth factor beta-type II receptor gene at chromosome 3p22 in human lung cancers with chromosome 3p deletions.

M Tani1, S Takenoshita, T Kohno, K Hagiwara, Y Nagamachi, C C Harris, J Yokota.   

Abstract

Mutations in the transforming growth factor beta-type II receptor (TGFbeta RII) gene have been detected in several types of human cancers that represent the phenotype of genomic instability. The TGFbeta RII gene has been mapped to chromosome 3p, on which loss of heterozygosity (LOH) was frequently detected in both small cell lung carcinoma (SCLC) and non-small cell lung carcinoma (NSCLC). To investigate whether the TGFbeta RII gene on 3p22 is inactivated in lung cancers, we examined 35 sporadic lung cancers (15 SCLC and 20 NSCLC) with LOH on 3p for mutations of the TGFbeta RII gene. We previously produced eight intron based primer pairs for mutational analysis of the entire coding region of the TGFbeta RII gene. Using these primers, we screened for mutations of the TGFbeta RII gene by polymerase chain reaction-single strand conformational polymorphism (PCR-SSCP) analysis. A mutation was detected in a case of SCLC: one base insertion in the polyadenine tract of exon 3. This tumor showed the replication error (RER) phenotype. There were no mutations in exons 1, 2, 4, 5, 6 and 7. These results indicate that the polyadenine tract is a mutational hot spot in the TGFbeta RII gene in RER positive tumors, and that TGFbeta RII mutations occur rarely in lung cancers with LOH on chromosome 3p.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9163705     DOI: 10.1093/carcin/18.5.1119

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  6 in total

1.  Evaluation of the prognostic value of TGF-β superfamily type I receptor and TGF-β type II receptor expression in nasopharyngeal carcinoma using high-throughput tissue microarrays.

Authors:  Wenling Zhang; Zhaoyang Zeng; Songqing Fan; Jieru Wang; Jianbo Yang; Yanhong Zhou; Xiayu Li; Donghai Huang; Fang Liang; Minghua Wu; Ke Tang; Li Cao; Xiaoling Li; Wei Xiong; Guiyuan Li
Journal:  J Mol Histol       Date:  2012-03-06       Impact factor: 2.611

2.  Loss of transforming growth factor beta type II receptor increases aggressive tumor behavior and reduces survival in lung adenocarcinoma and squamous cell carcinoma.

Authors:  Stephen P Malkoski; Sarah M Haeger; Timothy G Cleaver; Karen J Rodriguez; Howard Li; Shi-Long Lu; William J Feser; Anna E Barón; Daniel Merrick; Jessyka G Lighthall; Hideaki Ijichi; Wilbur Franklin; Xiao-Jing Wang
Journal:  Clin Cancer Res       Date:  2012-03-07       Impact factor: 12.531

3.  TGFBR2 mutation predicts resistance to immune checkpoint inhibitors in patients with non-small cell lung cancer.

Authors:  Teng Li; Han Wang; Jiachen Xu; Chengcheng Li; Yudong Zhang; Guoqiang Wang; Yutao Liu; Shangli Cai; Wenfeng Fang; Junling Li; Zhijie Wang
Journal:  Ther Adv Med Oncol       Date:  2021-08-14       Impact factor: 8.168

4.  Inactivation of the transforming growth factor beta type II receptor in human small cell lung cancer cell lines.

Authors:  S Hougaard; P Nørgaard; N Abrahamsen; H L Moses; M Spang-Thomsen; H Skovgaard Poulsen
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

5.  Mutations and reduced expression of the transforming growth factor-beta receptor II gene in rat lung adenocarcinomas induced by N-nitrosobis-(2-hydroxypropyl)amine.

Authors:  T Tsujiuchi; Y Sasaki; M Tsutsumi; Y Konishi
Journal:  Jpn J Cancer Res       Date:  2000-11

6.  EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway.

Authors:  Fumihiko Murai; Daizo Koinuma; Aya Shinozaki-Ushiku; Masashi Fukayama; Kohei Miyaozono; Shogo Ehata
Journal:  Cell Discov       Date:  2015-09-22       Impact factor: 10.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.